BioNTech Teams up With Sanofi to Target Solid Tumors in $91.5 Million Deal

Days ahead of the J.P. Morgan Healthcare Conference, Germany-based BioNTech extended its three-year-old collaboration with Sanofi as the companies look to co-develop the first cancer immunotherapy candidate for solid tumors. As part of the deal, the French pharma giant will invest about $91.5 million in equity in BioNTech, a privately-held company.
Read more...

;